Real-world data registry aims to bridge the evidence gap in multiple sclerosis research

By Vassia Barba

- Last updated on GMT

(Image: Getty/sudok1)
(Image: Getty/sudok1)

Related tags Corrona Data

Roche’s Genentech becomes the first pharmaceutical company included in the Corrona Multiple Sclerosis Registry, to support clinical research.

The Corrona Multiple Sclerosis (MS) Registry, the sixth registry created by Corrona LLC, was established in 2017, in collaboration with the National MS Society, with the purpose of studying the real-world effectiveness and safety of approved therapies for MS.

The registry collects clinical data prospectively from both MS patients and their treating neurologists and then shares the data with clinical and research communities through journals and poster presentations at scientific conferences. So far, over 700 patients are enrolled in the project.

In addition to collaborating with pharmaceutical companies, Corrona also sponsors academic research across all the registries.

Executive VP of Research at the National MS Society, Bruce Bebo said the MS registry will “provide the real-world context needed to make informed treatment decisions.”

According to Aaron Miller, Scientific Co-Director at the registry, reviewing data from the registry can, “provide valuable insight into the impact of treatments on clinical outcomes and quality of life for MS patients.”

The other registries created by Corrona are: The Rheumatoid Arthritis Registry, the Psoriasis Registry, the Psoriatic Arthritis and Spondyloarthritis Registry, the Inflammatory Bowel Disease Registry, the CERTAIN Rheumatoid Arthritis Registry and the Japan RA Registry.

Corrona’s registries collaborate with over 400 participating investigator sites, while the data have been used in over 140 per reviewed manuscripts and 430 abstracts.

The company has conducted active safety surveillance to support regulatory commitments for 14 new drug approvals, including formal post authorization safety studies.

Related news

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more